Commissioned for the 3rd BioCentury China Healthcare Summit (Oct. 18-19, 2016, Shanghai), this exclusive report discusses the latest trends shaping the biopharma and medtech industries in China.
How biopharma business models are changing in China to meet evolving customer needs;
China's latest policy initiatives meant to support biopharma innovation;
The latest trends impacting patient access to mature and innovative drugs in China;
Updated views on McKinsey's annual China Drug Innovation Index (CDII); and
Key trends shaping the medtech environment in China.
Download the Whitepaper
To download Building Bridges to Innovation 2016, please click the DOWNLOAD link below.
Notice
Terms, Conditions & Privacy Policy
By requesting this White Paper, you hereby Consent to and Agree your personal data will be processed by BioCentury Inc. and McKinsey & Co., the sponsor of the White Paper, in connection with the specific uses set forth below.
All information you provide is deemed to be voluntary. You Consent and Agree the information you provide will be used by BioCentury and McKinsey & Co. to provide you with the White Paper. You Consent and Agree that your information will be governed by the BioCentury Privacy Policy and that the information will be stored on BioCentury’s servers in the U.S. You also Consent and Agree that BioCentury will share your information with McKinsey & Co., which will use your information in accordance with its Privacy Policy.
Also, you agree that BioCentury may use your information to send you notices about BioCentury publications, products, conferences and services that are of interest to life sciences professionals and investors like yourself, along with notices about conferences and offers from other companies we believe will be of interest to you. Your information is not otherwise shared with any other third parties for marketing purposes.
BioCentury’s Privacy Policy allows you to alter your Consent at any time.